FORT COLLINS- A group of plaintiffs recently filed a motion with the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all federally filed Zantac lawsuits into one court for pre-trial proceedings.
The plaintiffs assert that all the pending actions involve common factual questions—namely, that plaintiffs purchased Zantac (ranitidine) and were exposed to the carcinogen N-nitrosodimethylamine (NDMA).
Zantac has been sold in the U.S. for more than 30 years, the plaintiffs state, and “every one of the millions of the drug’s consumers have been exposed to dangerous levels of NDMA and many thousands of those consumers have contracted cancer as a result.”
Online supplement company Valisure filed a Citizen’s Petition on September 9, 2019, urging the Food and Drug Administration (FDA) to recall all Zantac and generic ranitidine products because of their potential to expose users to NDMA. The company noted at the time that it’s own internal testing on the products had revealed high levels of NDMA “in every lot tested, across multiple manufacturers and dosage forms of the drug ranitidine.”